Microwave Ablation Clinical Trial
— MWAvsRFAOfficial title:
Microwave Ablation Versus Radiofrequency Ablation for the Treatment of Severe Complicated Monochorionic Pregnancies in the Peking University Third Hospital : A Pilot Randomised Controlled Trial
Verified date | June 2020 |
Source | Peking University Third Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Complicated pregnancies refer some special complications, including twin to twin transfusion
syndrome(TTTS), twin reverse arterial perfusion(TRAP), selective intrauterine fetal growth
restriction(sIUGR), twin anemia-polycythemia sequence(TAPS), one fetal death or structural
abnormalities, etc. Complicated twins are often associated with high perinatal morbidity and
mortality. Severe complicated twins can be treated with fetal-reduction surgery during
pregnancy, which can improve the survival rate of retained fetuses and reduce the disability
rate. The managements include mechanical umbilical cord ligation or thermal coagulation
obliteration, such as bipolar coagulation (BCC), radiofrequency ablation (RFA), and laser
coagulation.Nowadays radiofrequency ablation reduction is the most common, which processes a
higher survival rate and fewer maternal and fetal complications compared with other
ways.Latest experience suggests that microwave ablation(MWA) is also easy to be used and the
therapeutic effect is similar with RFA, but there is no convincing evidence. Compared with
radiofrequency ablation, MWA has the advantages of simple operation and time, and avoids the
problems of tissue carbonization, drying and heat sink effect. For fetation reduction
surgery, the main advantage is that the endothermic effect near the blood vessels is smaller,
which enables microwave fetation reduction to have a larger ablation range and a higher
thermal effect. This study is comparing Microwave Ablation(MWA) and radiofrequency ablation
(RFA) methods for selective fetal reduction in the treatment of complicated monochorionic
(MC) multifetal gestations.
This is a pilot randomised controlled trial(RCT) of 60 patients who undergo selective fetal
reduction. The subjects of this study were all pregnant women and their offspring who
underwent reduction surgery in the third hospital of Beijing University, and patients are
randomly assigned 1:1 to different intervention groups by parallel design. The outcome
evaluators were blind. Collecting their surgery, clinical information and maternal and fetal
complications at a week and a month after surgery, 42 days and 6 months after delivery, to
verify the safety and efficacy of MWA, and find a better treatment plan for complicated
monochorionic pregnancies .The primary outcome was neonatal survival rate.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | November 1, 2020 |
Est. primary completion date | October 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Complicated monochorionic pregnancies women; 2. Having the indication of selective reduction;(TTTS III or IV, TRAP, severe sIUGR, Twin malformation inconsistency or stillbirth,three or more fetuses with monochorionic pregnancies requiring reducing the number of fetuses) 3. The reduction surgery should be done after 15 weeks of gestation; 4. Willingness to participate in the trial and having provided written consent. Exclusion Criteria: 1. Preoperative examination shows that patient is not appropriate to undergoing reduction surgery, such as acute infection of the organ system, especially the urinary system. 2. Patients need to perform acute reduction surgery due to the progress of the disease and the surgery cannot be scheduled. 3. Other diseases that may affect the experimental results: neuropsychiatric diseases and congenital diseases. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital | Peking University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neonatal survival rate | The proportion of live births at 28 days postpartum | a month after delivery | |
Secondary | Surgical injury to fetal | Using MRI to assess postoperative thermal injury and nerve injury of fetus | at 28 weeks gestation | |
Secondary | Postoperative complications | Frequency of PPROM, premature delivery, frequency of infection, procedure-to-delivery interval, <28 weeks of intrauterine fetal death/abortion, >28 weeks of intrauterine fetal deat and <32 weeks premature delivery | at delivery | |
Secondary | Perinatal outcomes | Using Apgar Score to assess neonatal asphyxia(Heart rate, respiration, muscle tone, laryngeal reflex and skin color within one minute after birth are taken as the basis, each item is 0~2 points, the full mark is 10 points. 8~10 belong to normal newborns. 4~7 can be classified as mild asphyxiation, 0~3 as severe asphyxiation) | a week after delivery | |
Secondary | Growth of the children | The height of the surviving fetus at 6 months | 6 months postpartum |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04626986 -
Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor
|
N/A | |
Completed |
NCT05068076 -
Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
|
N/A | |
Not yet recruiting |
NCT03490890 -
Microwave Ablation in Ground Glass Nodules
|
Phase 2 | |
Completed |
NCT06031129 -
Butorphanol in Pain Following Ablation for Hepatic Tumor
|
N/A | |
Recruiting |
NCT03082378 -
Central Obesity and Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT03609268 -
Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT03963726 -
Clinical Efficacy of Stereotactic Radiotherapy and Microwave Ablation for Liver Metastases From Colorectal Cancer.
|
N/A | |
Recruiting |
NCT05361538 -
Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm
|
N/A | |
Recruiting |
NCT05444478 -
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT05990257 -
CMRA for US-guided-MWA of Liver Tumors
|
N/A | |
Recruiting |
NCT03286413 -
Comparison of Microwave Ablation With Cryoablation for Breast Tumor
|
N/A | |
Recruiting |
NCT03277716 -
Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
|
N/A | |
Terminated |
NCT04803890 -
"No-Touch" Radiofrequency Ablation for Small Hepatocellular Carcinoma (≤ 3cm): A Prospective Multicenter Study
|
N/A |